252 related articles for article (PubMed ID: 8679819)
1. [Cyclosporin A in the treatment of Eaton-Lambert myasthenic syndrome].
Yuste Ara JR; Beloqui Ruiz O; Artieda Gonzalez-Granda J; Herrero Santos JI; De la Peña Fernandez A; Prieto Valtueña J
An Med Interna; 1996 Jan; 13(1):25-6. PubMed ID: 8679819
[TBL] [Abstract][Full Text] [Related]
2. Lambert-Eaton myasthenic syndrome in childhood.
Kostera-Pruszczyk A; Ryniewicz B; Rowinska-Marcinska K; Dutkiewicz M; Kamińska A
Eur J Paediatr Neurol; 2009 Mar; 13(2):194-6. PubMed ID: 18585938
[TBL] [Abstract][Full Text] [Related]
3. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction.
Pellkofer HL; Voltz R; Kuempfel T
Muscle Nerve; 2009 Aug; 40(2):305-8. PubMed ID: 19609921
[TBL] [Abstract][Full Text] [Related]
4. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
McEvoy KM; Windebank AJ; Daube JR; Low PA
N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713
[TBL] [Abstract][Full Text] [Related]
5. Lambert-Eaton myasthenic syndrome in children.
Tsao CY; Mendell JR; Friemer ML; Kissel JT
J Child Neurol; 2002 Jan; 17(1):74-6. PubMed ID: 11913581
[TBL] [Abstract][Full Text] [Related]
6. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune disorders of neuromuscular transmission.
Mahadeva B; Phillips LH; Juel VC
Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
[TBL] [Abstract][Full Text] [Related]
8. Lambert-Eaton myasthenic syndrome.
Mareska M; Gutmann L
Semin Neurol; 2004 Jun; 24(2):149-53. PubMed ID: 15257511
[TBL] [Abstract][Full Text] [Related]
9. Manifestation of Lambert-Eaton myasthenic syndrome during last trimester of pregnancy.
Bayrak AO; Sandikci U; Yon SK; Onar MK
Int J Neurosci; 2010 Jun; 120(6):439-41. PubMed ID: 20504215
[TBL] [Abstract][Full Text] [Related]
10. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
[TBL] [Abstract][Full Text] [Related]
11. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
12. Monozygous twins with neuromuscular transmission defects at opposite sides of the motor endplate.
Punga AR; Nygren I; Askmark H; Stålberg EV
Acta Neurol Scand; 2009 Mar; 119(3):207-11. PubMed ID: 18684214
[TBL] [Abstract][Full Text] [Related]
13. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
Takamori M
J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
[TBL] [Abstract][Full Text] [Related]
14. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse.
Waterman SA; Lang B; Newsom-Davis J
Ann Neurol; 1997 Aug; 42(2):147-56. PubMed ID: 9266723
[TBL] [Abstract][Full Text] [Related]
15. [Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome].
Boutin E; Rey C; Romeu M; Pouget J; Franques J
Rev Med Interne; 2013 Aug; 34(8):493-6. PubMed ID: 23759215
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up in infantile-onset lambert-eaton myasthenic syndrome.
Portaro S; Parisi D; Polizzi A; Ruggieri M; Andreetta F; Bernasconi P; Toscano A; Rodolico C
J Child Neurol; 2014 Sep; 29(9):NP58-61. PubMed ID: 24114606
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of Lambert-Eaton myasthenic syndrome.
McEvoy KM
Neurol Clin; 1994 May; 12(2):387-99. PubMed ID: 8041348
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
[TBL] [Abstract][Full Text] [Related]
19. [Proximal muscle weakness, depressed tendon reflexes and autonomic dysfunction: the Lambert-Eaton myasthenic syndrome].
Wirtz PW; Kuks JB; Wintzen AR; Verschuuren JJ
Ned Tijdschr Geneeskd; 2001 Jan; 145(2):57-61. PubMed ID: 11225256
[TBL] [Abstract][Full Text] [Related]
20. [Lambert-Eaton myasthenic syndrome. Physiopathological aspects and therapeutic modalities].
Kuntzer T; Steck AJ; Fiorini E; Mirimanoff RO; Regli F
Rev Neurol (Paris); 1991; 147(12):819-24. PubMed ID: 1688363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
